Profile picture of Michael Huo

Dr Michael Huo

Profile picture of Michael Huo

MBBS, FRANZCR

Radiation Oncologist
Call
Referrals
Greenslopes
07 3099 8401

Dr Michael Huo is committed to ensuring his patients receive exceptional, evidence-based cancer care.

Biography

Dr Michael Huo is a radiation oncologist at Icon Cancer Centre Greenslopes and Icon Cancer Centre Redland. Raised in Brisbane, he completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) at the University of Queensland (UQ) in 2010. He subsequently commenced specialist radiation oncology training in Cairns, Toowoomba and Brisbane. Dr Huo completed a 12-month clinical fellowship at the world-renowned Princess Margaret Hospital in Toronto, Canada where he gained extensive experience in stereotactic radiosurgery and palliative radiation therapy. In 2019 he became the inaugural Gamma Knife Fellow at the Princess Alexandra Hospital before his appointment as a Radiation Oncology Staff Specialist in 2020.

Dr Huo is actively involved in medical education and research. He is the local principal investigator for an intracranial stereotactic radiosurgery study and has contributed a number of textbook chapters and peer-reviewed publications. Dr Huo has presented at national and international conferences and is also an examiner and senior lecturer at the UQ School of Medicine. He actively engages in medical education and mentorship with the Queensland Radiation Oncology Training Network and UQ medical students.

His clinical experience covers a range of malignancies with a special interest in brain metastases, benign intracranial tumours and conditions, genitourinary cancers and palliative radiation therapy. Dr Huo can converse in both English and Mandarin, and looks forward to working with patients in their language. 霍医生可以用英语和普通话和您交谈,并期待用您和您的家人所熟悉的语言为你们提供医疗服务。

Publications

  • Importance of Cobalt-60 Dose Rate and Biologically Effective Dose on Local Control for Intracranial Meningiomas Treated With Stereotactic Radiosurgery. M. Huo, M. Rose, M. van Prooijen, M. Cusimano, N. Laperriere, R. Heaton, F. Gentili, D. Payne, D. Shultz, P. Kongkham, S. Kalia, M. Schwartz, M. Bernstein, J. Spears, G. Zadeh, M. Hodaie & D. Tsang. Neurosurgery, 2022; 90: 140-147.

  • Outcomes Following Hypofractionated Stereotactic Radiotherapy to the Cavity After Surgery for Melanoma Brain Metastases. J. Gallo, S. Garimall, M. Shanker, J. Castelli, T. Watkins, S. Olson, M. Huo, M.C. Foote & M. Pinkham. Clinical Oncology (R Coll Radiol), 2021.

  • Renal Cell Carcinoma Metastasis to Meckel’s Cave Treated With Repeat Stereotactic Radiosurgery: A Case Report and Review of the Literature. J. Panizza, M. Pinkham, M. Foote, M. Shanker, K. Horwood & M. Huo. Cureus, 2021; 13.

  • Stereotactic radiotherapy for large vestibular schwannomas: Volume change following single fraction versus hypofractionated approaches. M. Huo, H. Foley, M. Pinkham, M. Shanker, A. Bernard, M. Jenkins, S. Olson, B. Hall, T. Watkins, C. Jones & M. Foote. Journal of Radiosurgery & SBRT (Stereotactic Body Radiation Therapy), 2020; 7. 11-17.

  • Efficacy of stereotactic radiosurgery for radiation-induced meningiomas. M. Huo, N. Laperriere, M. van Prooijen, D. Shultz, C. Coolens, M. Hodaie, M. Cusimano, F. Gentili, G. Zadeh, D. Payne, M. Schwartz & D. Tsang. Journal of Neuro-Oncology, 2020. 148(5).

Special Interests

Dr Michael Huo accepts referrals for all cancer types, with a special clinical interest in:

  • Brain and spine (CNS) cancer
  • Genitourinary cancer
  • Palliative care

Languages spoken

  • English
  • Mandarin

Visiting Locations

  • Princess Alexandra Hospital
  • Sunnybank Private Specialist Centre

Affiliations & Memberships

  • Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
  • International Stereotactic Radiosurgery Society (ISRS)
  • Leksell Gamma Knife Society (LGKS)
  • Royal Australian and New Zealand College of Radiologists (RANZCR)

Publications

  • Importance of Cobalt-60 Dose Rate and Biologically Effective Dose on Local Control for Intracranial Meningiomas Treated With Stereotactic Radiosurgery. M. Huo, M. Rose, M. van Prooijen, M. Cusimano, N. Laperriere, R. Heaton, F. Gentili, D. Payne, D. Shultz, P. Kongkham, S. Kalia, M. Schwartz, M. Bernstein, J. Spears, G. Zadeh, M. Hodaie & D. Tsang. Neurosurgery, 2022; 90: 140-147.

  • Outcomes Following Hypofractionated Stereotactic Radiotherapy to the Cavity After Surgery for Melanoma Brain Metastases. J. Gallo, S. Garimall, M. Shanker, J. Castelli, T. Watkins, S. Olson, M. Huo, M.C. Foote & M. Pinkham. Clinical Oncology (R Coll Radiol), 2021.

  • Renal Cell Carcinoma Metastasis to Meckel’s Cave Treated With Repeat Stereotactic Radiosurgery: A Case Report and Review of the Literature. J. Panizza, M. Pinkham, M. Foote, M. Shanker, K. Horwood & M. Huo. Cureus, 2021; 13.

  • Stereotactic radiotherapy for large vestibular schwannomas: Volume change following single fraction versus hypofractionated approaches. M. Huo, H. Foley, M. Pinkham, M. Shanker, A. Bernard, M. Jenkins, S. Olson, B. Hall, T. Watkins, C. Jones & M. Foote. Journal of Radiosurgery & SBRT (Stereotactic Body Radiation Therapy), 2020; 7. 11-17.

  • Efficacy of stereotactic radiosurgery for radiation-induced meningiomas. M. Huo, N. Laperriere, M. van Prooijen, D. Shultz, C. Coolens, M. Hodaie, M. Cusimano, F. Gentili, G. Zadeh, D. Payne, M. Schwartz & D. Tsang. Journal of Neuro-Oncology, 2020. 148(5).

Search

Contact us
Become a patient